Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

- PMLiVE

Biopharma’s Future: Made in China

The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise

- PMLiVE

Imfinzi aces survival challenge in lung cancer

Earlier treatment leads to much extended lives, data suggests

- PMLiVE

AstraZeneca chief on Brexit: “It’s going to be really painful”

Soriot also claims to be lowest paid CEO in sector

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

- PMLiVE

AZ prepares to file COPD triple, taking on rival GSK

Latest salvo in combination trials competition

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

- PMLiVE

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

European approvals for Amgen and AstraZeneca

- PMLiVE

FDA rejects Allergan’s uterine fibroid drug over safety concerns

Its investigational drug has been linked to 'serious' liver damage issues in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links